Bone curvature changes can predict the impact of treatment on cartilage volume loss in knee osteoarthritis: data from a 2-year clinical trial.
Knee bone curvature assessed by MRI was associated with OA cartilage loss. A recent knee OA trial demonstrated the superiority of chondroitin sulfate over celecoxib (comparator) at reducing cartilage volume loss (CVL) in the medial compartment (condyle). The main objectives were to identify which baseline bone curvature regions of interest (BCROI) best associated with CVL and investigate whether baseline BCROI and 2-year change are correlated with the protective effect of chondroitin sulphate on CVL.



This post hoc analysis of a clinical trial used the according-to-protocol population (chondroitin sulphate, n = 57; celecoxib, n = 63) baseline and 2-year MRI to assess bone curvature and CVL. Global optimum search identified the BCROI in the medial condyle using celecoxib as reference. Statistical analyses were performed with Pearson's correlation, Mann-Whitney U -test, Student's t -test and analysis of covariance.



The BCROI including the medial posterior condyle and lateral central condyle was found to correlate best with medial condyle CVL at 2 years ( r = 0.33, P = 0.008). In patients with a baseline BCROI value less than the median (more flattened bone), chondroitin sulphate demonstrated a protective effect on CVL compared with celecoxib in the medial compartment (P = 0.037). In patients with 2-year BCROI changes greater than the median (greater severity of bone flattening), chondroitin sulphate protected against CVL in the medial compartment, condyle and central plateau (P ⩽ 0.030).



This study is the first to demonstrate the feasibility and usefulness of bone curvature measurements to predict effectiveness of OA treatment on CVL. The results identify bone curvature as a potential novel biomarker for knee OA clinical trials.
Osteoarthritis Research Unit, University of Montreal Hospital Research Centre.
Jean-Pierre
JP
Raynauld
Osteoarthritis Research Unit, University of Montreal Hospital Research Centre.
Jean-Pierre
JP
Pelletier
Medical Imaging Research & Development, ArthroLab Inc., Montreal, Quebec, Canada.
Philippe
P
Delorme
Medical Imaging Research & Development, ArthroLab Inc., Montreal, Quebec, Canada.
Pierre
P
Dodin
Medical Imaging Research & Development, ArthroLab Inc., Montreal, Quebec, Canada.
François
F
Abram
Osteoarthritis Research Unit, University of Montreal Hospital Research Centre.
Johanne
J
Martel-Pelletier
D000328:Adult; D000368:Aged; D001847:Bone Diseases / Q000473:pathology*; D002357:Cartilage Diseases / Q000473:pathology; D002358:Cartilage, Articular / Q000473:pathology; D000068579:Celecoxib / Q000627:therapeutic use; D002809:Chondroitin Sulfates / Q000627:therapeutic use; D052246:Cyclooxygenase 2 Inhibitors / Q000627:therapeutic use; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009929:Organ Size / Q000502:physiology; D020370:Osteoarthritis, Knee / Q000188:drug therapy / Q000473:pathology*
D052246:Cyclooxygenase 2 Inhibitors; D002809:Chondroitin Sulfates; D000068579:Celecoxib
bone curvature; cartilage volume; celecoxib; chondroitin sulfate; knee; osteoarthritis; quantitative MRI